Lupus nephritis

HJ Anders, R Saxena, M Zhao, I Parodis… - Nature reviews Disease …, 2020 - nature.com
Lupus nephritis (LN) is a form of glomerulonephritis that constitutes one of the most severe
organ manifestations of the autoimmune disease systemic lupus erythematosus (SLE). Most …

Glomerulonephritis: immunopathogenesis and immunotherapy

HJ Anders, AR Kitching, N Leung… - Nature Reviews …, 2023 - nature.com
Abstract 'Glomerulonephritis'(GN) is a term used to describe a group of heterogeneous
immune-mediated disorders characterized by inflammation of the filtration units of the kidney …

KDIGO 2021 clinical practice guideline for the management of glomerular diseases

BH Rovin, SG Adler, J Barratt, F Bridoux… - Kidney …, 2021 - kidney-international.org
Glomerular disease, be it primary or secondary, occurring in the setting of systemic
autoimmune diseases, infections, drugs, or malignancy, affects individuals of all ages. In …

B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial

RA Furie, G Aroca, MD Cascino, JP Garg… - Annals of the …, 2022 - ard.bmj.com
Objective Randomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed
to show benefit in proliferative lupus nephritis (LN). We compared obinutuzumab, a …

2019 update of the joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA …

A Fanouriakis, M Kostopoulou, K Cheema… - Annals of the …, 2020 - ard.bmj.com
Objective To update the 2012 EULAR/ERA–EDTA recommendations for the management of
lupus nephritis (LN). Methods Following the EULAR standardised operating procedures, a …

Systemic lupus erythematosus: diagnosis and clinical management

A Fava, M Petri - Journal of autoimmunity, 2019 - Elsevier
Systemic lupus erythematosus (SLE) is a worldwide chronic autoimmune disease which
may affect every organ and tissue. Genetic predisposition, environmental triggers, and the …

Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis

D Jayne, B Rovin, EF Mysler, RA Furie… - Annals of the …, 2022 - ard.bmj.com
Objective To assess the efficacy and safety of the type I interferon receptor antibody,
anifrolumab, in patients with active, biopsy-proven, Class III/IV lupus nephritis. Methods This …

Management strategies and future directions for systemic lupus erythematosus in adults

L Durcan, T O'Dwyer, M Petri - The Lancet, 2019 - thelancet.com
Systemic lupus erythematosus (SLE) is an autoimmune disease characterised by the loss of
self-tolerance and formation of nuclear autoantigens and immune complexes resulting in …

Lupus nephritis: clinical presentations and outcomes in the 21st century

M Gasparotto, M Gatto, V Binda, A Doria… - Rheumatology, 2020 - academic.oup.com
Lupus nephritis (LN) is a frequent and severe manifestation of SLE. Along the decades, the
epidemiology of LN and its clinical presentation have been changing. However, even …

[HTML][HTML] Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National …

IM Bajema, S Wilhelmus, CE Alpers, JA Bruijn… - Kidney international, 2018 - Elsevier
We present a consensus report pertaining to the improved clarity of definitions and
classification of glomerular lesions in lupus nephritis that derived from a meeting of 18 …